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Several devices are used for long-acting muscarinic
antagonist (LAMA)/long-acting b2 agonist (LABA)
inhalation therapy for chronic obstructive pulmonary
disease (COPD) patients but what is the optimum
device? On the basis of Bayesian network meta-
analysis, all the LAMA/LABA fixed-dose combina-
tions are at present evaluated as having similar
efficacy in terms of forced expiratory volume in 1
second (FEV1).1 However, in recent years, the asso-
ciation between the residual volume and the symp-
toms of COPD has been drawing attention. In Japan,
the devices available for LAMA/LABA are dry-
powder inhalers (DPIs) and soft-mist inhalers (SMIs).
A previous report showed improvements in functional
residual capacity and residual volume (RV) with an
SMI-type LAMA/LABA over the same LABA or
LAMA given as a single agent.2 Other researchers
have reported that the deposition pattern within the
lungs was more peripheral for SMI than for DPI.3
Since April 2015, among 9 patients in our hospital
with COPD who sequentially used 2 kinds of LAMA/
LABA devices, 8 patients (mean age: 77.5 years;
range: 67–87 years; mean pack years: 84.2; range:
33.8–144; all patients were male) initially took DPI-
glycopyrronium plus indacaterol for at least 8 weeks
and then switched to SMI-tiotropium plus olodaterol.
One patient switched from SMI to DPI. Because SMI-
tiotropium plus olodaterol became commercially
available 2 years after DPI-glycopyrronium plus inda-
caterol had become available in Japan, most patients
in this study switched from DPI to SMI. All patients
were using LAMA as a monotherapy before they
started the combination treatment. We examined
changes in lung function measures by comparing the
measures taken before and after the switch to the SMI
device. The first “before switch” lung function was
measured on the day it was switched and the last
“after switch” lung function was measured after 6 to
10 weeks. The lung function values were measured 2
to 8 hours after the last inhalation dose, and the time
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point of the “before switch” and “after switch” lung
function measurements was almost identical for each
patient. The appropriate inhalation technique for both
devices was confirmed for every patient when the
patient started the respective inhalations. This study
was approved by the Institutional Review Board of
our hospital. Changes in lung function test values
were evaluated using the Wilcoxon signed-rank test
(Table 1). Although no significant difference was
found in forced expiratory volume in 1 second
(FEV1) before and after the use of the SMI device,
the vital capacity (VC) (p ¼ 0.012) and % predicted
VC (p¼ 0.012) differed significantly, with an average
improvement of200 mL in VC after the switch from
the DPI to the SMI. These findings could reflect the
possible superiority of tiotropium plus olodaterol over
glycopyrronium plus indacaterol or of the SMI-type
inhalation device or of both. In the treatment of
COPD, not only FEV1 but also the increase in VC
related to air trapping caused by small airway diseases
should be considered. Improvement in VC leads to
decreased RV, increased effective ventilation, and
alleviation of rapid and superficial breathing. This is
a pharmacologic effect comparable to the lung vol-
ume reduction surgery (LVRS). This could be consid-
ered a “pharmacologic LVRS effect.”
LAMA/LABA combination has increased the
number of treatment choices, and identifying the most
appropriate device for each COPD phenotype is nec-
essary. Patients with COPD who do not show satis-
factory responses to DPI-glycopyrronium plus
indacaterol may benefit from switching to SMI-
tiotropium plus olodaterol, especially from the view-
point of increasing the VC. Here we have reported a
retrospective evaluation of routinely treated patients.
The sequence of the two treatments was not rando-
mized. Therefore, the findings can only be indicative
of what might happen in a larger population. A
planned prospective investigation is required to verify
this contention.
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Table 1. Changes of lung function parameters after switching from DPI to SMI.a
VC % VC FVC % FVC FEV1 % FEV1 FEV1%
Average change 224 ml 6.78% 271 ml 8.18% 146 ml 7.97% 2.15%
Standard deviation 0.17 5.12 0.44 14.00 0.17 9.05 3.26
Absolute value for
Z score (p value)
2.52 (0.012) 2.52 (0.012) 1.54 (0.12) 1.54 (0.12) 1.89 (0.058) 1.82 (0.069) 1.54 (0.12)
DPI: dry-powder inhaler; SMI: soft-mist inhalers; VC: vital capacity; FVC: forced vital capacity; FEV1: forced expiratory volume in
1 second.
aSignificant increase in vital capacity and % vital capacity was found after switching from DPI to SMI (Wilcoxon signed rank test).
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